BioNTech SE (BNTX) Reports Q1 EPS of EUR4.39
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
BioNTech Announces First Quarter 2021 Financial Results and Corporate Update
May 10, 2021 7:00 AM EDTMore than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTechs oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing... More
